# US 2011/0300122 A1 · Method for treating a patient

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0300122 A1
- Document ID: US20110300122A1
- Status: Published application
- Kind: A1
- Application number: 12/793,992
- Filed: 2010-06-04
- Published: 2011-12-08
- Earliest claimed: 2010-06-04
- Inventors: Dietmar Fries; Michael Rieger
- Web page: https://patentgrep.com/patent/US20110300122A1

## CPC

- A61K 38/4846: {Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)}
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Intra-arterial administering at least one blood coagulation to a bleeding patient is provided, together with a pharmaceutical composition therefor.

## Claims

### Claim 1

A method for treating a patient comprising the administration of a blood coagulation factor, wherein the blood coagulation factor is administered intra-arterially.

### Claim 2 (depends on 1)

The method of claim 1, wherein the patient suffers from internal bleeding.

### Claim 3 (depends on 2)

The method of claim 2, wherein the Internal bleeding results from injuries to arterial blood vessels.

### Claim 4 (depends on 1)

The method of claim 1, wherein the patient suffers from pelvic injuries.

### Claim 5 (depends on 4)

The method of claim 4, wherein the pelvic injury is a complex pelvic trauma.

### Claim 6 (depends on 4)

The method of claim 4, wherein the pelvic Injuries comprise disrupted vessels selected from the group of the arteria iliaca communis, the arteria iliaca externa, the arteria iliaca interna and branches thereof.

### Claim 7 (depends on 1)

The method of claim 1, wherein the blood coagulation factor is proconvertin (FVII).

### Claim 8 (depends on 7)

The method of claim 7, wherein the blood coagulation factor is activated proconvertin (FVIIa).

### Claim 9 (depends on 8)

The method of claim 8, wherein the blood coagulation factor is recombinant activated proconvertin (rFVIIa).

### Claim 10 (depends on 1)

The method of claim 1, wherein the method is intended for the emergency treatment.

### Claim 11 (depends on 1)

The method of claim 1, wherein the method is intended for a non-surgical treatment.

### Claim 12 (depends on 1)

The method of claim 1, wherein the method is intended to be carried out in a mobile treatment facility.

### Claim 13 (depends on 1)

The method of claim 1, wherein the administration of the blood coagulation factor is a one-time administration of a single dose of the blood coagulation factor.

### Claim 14 (depends on 1)

The method of claim 1, wherein between about 50 and about 150 μg coagulation factor per kg body weight are administered.

### Claim 15 (depends on 14)

The method of claim 14, wherein between about 75 and about 125 μg coagulation factor per kg body weight are administered.

### Claim 16 (depends on 15)

The method of claim 15, wherein between about 90 and about 110 μg coagulation factor per kg body weight are administered.

### Claim 17

A pharmaceutical composition for the intra-arterial administration comprising at least one blood coagulation factor.

### Claim 18 (depends on 17)

The composition of claim 17, wherein the composition is Intended for the treatment of internal bleeding.

### Claim 19 (depends on 18)

The composition of claim 18, wherein the internal bleeding results from injuries to arterial blood vessels.

### Claim 20 (depends on 17)

The composition of claim 17, wherein the composition is intended for the treatment of pelvic injuries.

### Claim 21 (depends on 17)

The composition of claim 17, wherein the pelvic injury is a complex pelvic trauma.

### Claim 22 (depends on 17)

The composition of claim 17, wherein the pelvic injuries comprise disrupted vessels selected from the group of the arteria iliaca communis, the arteria iliaca externa, the arteria iliaca interna and branches thereof.

### Claim 23 (depends on 17)

The composition of claim 17, wherein the blood coagulation factor is proconvertin (FVII).

### Claim 24 (depends on 23)

The composition of claim 23, wherein the blood coagulation factor is activated proconvertin (FVIIa).

### Claim 25 (depends on 24)

The composition of claim 24, wherein the blood coagulation factor is recombinant, activated proconvertin (rFVIIa).

### Claim 26 (depends on 17)

The composition of claim 17, wherein the composition is intended for the use in emergency treatment.

### Claim 27 (depends on 17)

The composition of claim 17, wherein the composition is intended for the use in non-surgical treatment.

### Claim 28 (depends on 17)

The composition of claim 17, wherein the composition is intended for the use in a mobile treating facility.

### Claim 29 (depends on 17)

The composition of claim 17, wherein the composition is intended for a one-time administration of a single dose of the blood coagulation factor.
